Investors & Media

Ionis provides update on development program evaluating PCSK9 antisense medicine for the treatment of hypercholesterolemia

ION449 (AZD8233) met primary endpoint in Phase 2b SOLANO study for patients with hypercholesterolemia ION449 will not advance into Phase 3 development based on pre-specified criteria CARLSBAD, Calif. , Sept. 23, 2022 /PRNewswire/ — Ionis Pharmaceuticals, Inc.

Read more
You are now leaving to visit